Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706102 | 0.88 | APAF1 (0.37) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| SCHEMBL451543 | 0.88 | APAF1 (0.37) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| Hydrochloric Acid SCHEMBL4708232 | 0.88 | APAF1 (0.37) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| Hydrochloric Acid SCHEMBL4708235 | 0.88 | APAF1 (0.37) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| SCHEMBL4706098 | 0.88 | APAF1 (0.37) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| SCHEMBL9981210 | 0.85 | CYP1A2 (0.38) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| SCHEMBL14138403 | 0.85 | SMYD2 (0.36) | SMYD2CYP1A2CYP2D6CYP3A4HTT | |
| SCHEMBL5685150 | 0.84 | ESRRB (0.39) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 | |
| SCHEMBL5685142 | 0.84 | ESRRB (0.39) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 | |
| SCHEMBL5873084 | 0.84 | ESRRB (0.39) | SMYD2CYP3A4HTTSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7112676-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1560832-A1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | DERMATAKIS APOSTOLOS (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004041822-A1 | PYRIMIDO[4,5-D]PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075272-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FYN | SMYD2 3157/4885CYP1A2 3642/4885CYP2D6 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.